-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5

Benzinga·06/16/2026 12:17:45
Listen to the news
Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $8 to $5.